How This Works
IGF-1 LR3 is a synthetic analog of human insulin-like growth factor-1 engineered with an N-terminal extension (13 amino acids) and a glutamic acid substitution at position 3, resulting in significantly reduced binding affinity to IGF binding proteins. This modification extends the peptide’s half-life from minutes (native IGF-1) to several hours and enhances systemic bioavailability.
The extended circulation time allows for once-daily administration protocols in research settings. Unlike native IGF-1, which requires frequent dosing, IGF-1 LR3 maintains more stable plasma levels throughout the day. The peptide exhibits anabolic and metabolic activities through IGF-1 receptor binding, though it has never been approved for therapeutic human use and remains confined to research applications.
Studies examining IGF-1 and its analogs demonstrate effects on cellular growth, protein synthesis, and metabolic regulation. The insulin-like properties of IGF-1 LR3 necessitate careful attention to blood glucose management, particularly during initial dosing and titration phases.
Potential Benefits & Side Effects
Observations from preclinical and clinical literature on IGF-1 and its analogs.
Potential Research Observations:
Enhanced anabolic signaling and protein synthesis in target tissues.
Extended bioavailability compared to native IGF-1 due to reduced binding protein interaction.
Metabolic effects through IGF-1 receptor pathways.
Important Safety Considerations:
Hypoglycemia risk: The most significant concern with IGF-1 LR3 is its insulin-like effect on blood glucose; symptoms may include shakiness, confusion, sweating, or dizziness. Always administer with food and monitor for glucose-related symptoms.
No FDA approval: IGF-1 LR3 has never received regulatory approval for human therapeutic use and is restricted to research applications.
Injection site reactions: Mild local irritation, redness, or discomfort may occur; proper technique and site rotation minimize these effects.
Dose-dependent effects: Safety concerns increase substantially at doses exceeding 50–60 mcg/day; conservative dosing protocols are strongly recommended.
Receptor desensitization: Continuous use beyond 6–8 weeks may lead to diminished response; cycling protocols (e.g., 8 weeks on, 4–8 weeks off) are commonly employed.
Disclaimer:
The information provided in this article is for educational and informational purposes only and is not intended as medical advice. These statements have not been evaluated by the FDA or Health Canada. Peptides and other compounds discussed are intended for research purposes only and are not approved for human consumption unless prescribed by a licensed medical professional. Always consult your healthcare provider before starting any new protocol, supplement, or treatment.